vs

Side-by-side financial comparison of CAVA GROUP, INC. (CAVA) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

CAVA GROUP, INC. is the larger business by last-quarter revenue ($280.6M vs $152.6M, roughly 1.8× CATALYST PHARMACEUTICALS, INC.). CATALYST PHARMACEUTICALS, INC. runs the higher net margin — 34.5% vs 6.5%, a 28.0% gap on every dollar of revenue. On growth, CAVA GROUP, INC. posted the faster year-over-year revenue change (20.2% vs 7.6%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $19.2M).

Cava, also referred to as Cava Grill, is an American Mediterranean fast casual restaurant chain with locations across the United States. Cava is owned by the publicly traded Cava Group, which purchased Zoës Kitchen in August 2018. The combined company is the largest restaurant operator in the Mediterranean category in the U.S. restaurant industry. Cava also produces a line of Mediterranean dips, spreads, and dressings that are sold in grocery stores across the US. As of May 2023, all Zoës Kit...

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CAVA vs CPRX — Head-to-Head

Bigger by revenue
CAVA
CAVA
1.8× larger
CAVA
$280.6M
$152.6M
CPRX
Growing faster (revenue YoY)
CAVA
CAVA
+12.6% gap
CAVA
20.2%
7.6%
CPRX
Higher net margin
CPRX
CPRX
28.0% more per $
CPRX
34.5%
6.5%
CAVA
More free cash flow
CPRX
CPRX
$25.7M more FCF
CPRX
$44.9M
$19.2M
CAVA

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CAVA
CAVA
CPRX
CPRX
Revenue
$280.6M
$152.6M
Net Profit
$18.4M
$52.7M
Gross Margin
82.9%
Operating Margin
7.0%
40.5%
Net Margin
6.5%
34.5%
Revenue YoY
20.2%
7.6%
Net Profit YoY
-7.0%
-5.8%
EPS (diluted)
$0.16
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAVA
CAVA
CPRX
CPRX
Q4 25
$152.6M
Q3 25
$280.6M
$148.4M
Q2 25
$331.8M
$146.6M
Q1 25
$141.4M
Q4 24
$141.8M
Q3 24
$233.5M
$128.7M
Q2 24
$259.0M
$122.7M
Q1 24
$98.5M
Net Profit
CAVA
CAVA
CPRX
CPRX
Q4 25
$52.7M
Q3 25
$18.4M
$52.8M
Q2 25
$25.7M
$52.1M
Q1 25
$56.7M
Q4 24
$55.9M
Q3 24
$19.7M
$43.9M
Q2 24
$14.0M
$40.8M
Q1 24
$23.3M
Gross Margin
CAVA
CAVA
CPRX
CPRX
Q4 25
82.9%
Q3 25
84.7%
Q2 25
85.9%
Q1 25
87.3%
Q4 24
84.7%
Q3 24
26.7%
85.0%
Q2 24
25.2%
87.4%
Q1 24
87.3%
Operating Margin
CAVA
CAVA
CPRX
CPRX
Q4 25
40.5%
Q3 25
7.0%
44.7%
Q2 25
4.7%
45.2%
Q1 25
44.8%
Q4 24
44.3%
Q3 24
6.9%
39.6%
Q2 24
3.6%
44.2%
Q1 24
27.5%
Net Margin
CAVA
CAVA
CPRX
CPRX
Q4 25
34.5%
Q3 25
6.5%
35.6%
Q2 25
7.7%
35.6%
Q1 25
40.1%
Q4 24
39.4%
Q3 24
8.5%
34.1%
Q2 24
5.4%
33.2%
Q1 24
23.6%
EPS (diluted)
CAVA
CAVA
CPRX
CPRX
Q4 25
$0.40
Q3 25
$0.16
$0.42
Q2 25
$0.22
$0.41
Q1 25
$0.45
Q4 24
$0.44
Q3 24
$0.17
$0.35
Q2 24
$0.12
$0.33
Q1 24
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAVA
CAVA
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$290.2M
$709.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$750.7M
$954.3M
Total Assets
$1.3B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAVA
CAVA
CPRX
CPRX
Q4 25
$709.2M
Q3 25
$290.2M
$689.9M
Q2 25
$289.4M
$652.8M
Q1 25
$580.7M
Q4 24
$517.6M
Q3 24
$343.7M
$442.3M
Q2 24
$329.1M
$375.7M
Q1 24
$310.4M
Stockholders' Equity
CAVA
CAVA
CPRX
CPRX
Q4 25
$954.3M
Q3 25
$750.7M
$920.2M
Q2 25
$726.2M
$856.0M
Q1 25
$794.3M
Q4 24
$727.6M
Q3 24
$595.4M
$660.9M
Q2 24
$580.8M
$608.7M
Q1 24
$561.4M
Total Assets
CAVA
CAVA
CPRX
CPRX
Q4 25
$1.1B
Q3 25
$1.3B
$1.1B
Q2 25
$1.2B
$971.9M
Q1 25
$908.9M
Q4 24
$851.4M
Q3 24
$1.0B
$772.0M
Q2 24
$1.0B
$706.4M
Q1 24
$646.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAVA
CAVA
CPRX
CPRX
Operating Cash FlowLast quarter
$60.3M
$44.9M
Free Cash FlowOCF − Capex
$19.2M
$44.9M
FCF MarginFCF / Revenue
6.8%
29.4%
Capex IntensityCapex / Revenue
14.7%
0.0%
Cash ConversionOCF / Net Profit
3.28×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$49.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAVA
CAVA
CPRX
CPRX
Q4 25
$44.9M
Q3 25
$60.3M
$32.4M
Q2 25
$38.6M
$71.3M
Q1 25
$60.0M
Q4 24
$70.9M
Q3 24
$48.9M
$72.9M
Q2 24
$38.4M
$64.1M
Q1 24
$31.9M
Free Cash Flow
CAVA
CAVA
CPRX
CPRX
Q4 25
$44.9M
Q3 25
$19.2M
Q2 25
$2.7M
$71.3M
Q1 25
Q4 24
$70.8M
Q3 24
$22.7M
$72.6M
Q2 24
$4.7M
$64.1M
Q1 24
$31.7M
FCF Margin
CAVA
CAVA
CPRX
CPRX
Q4 25
29.4%
Q3 25
6.8%
Q2 25
0.8%
48.6%
Q1 25
Q4 24
49.9%
Q3 24
9.7%
56.4%
Q2 24
1.8%
52.3%
Q1 24
32.2%
Capex Intensity
CAVA
CAVA
CPRX
CPRX
Q4 25
0.0%
Q3 25
14.7%
0.0%
Q2 25
10.8%
0.0%
Q1 25
0.0%
Q4 24
0.1%
Q3 24
11.2%
0.2%
Q2 24
13.0%
0.0%
Q1 24
0.2%
Cash Conversion
CAVA
CAVA
CPRX
CPRX
Q4 25
0.85×
Q3 25
3.28×
0.61×
Q2 25
1.50×
1.37×
Q1 25
1.06×
Q4 24
1.27×
Q3 24
2.48×
1.66×
Q2 24
2.74×
1.57×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CAVA
CAVA

Restaurant Revenue$278.2M99%
Rewards$2.8M1%
CPG Revenue And Other$2.4M1%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons